
About Excision
Excision is a Healthcare company based in Philadelphia (United States) founded in 2015. CRISPR-based therapies are developed to cure viral infectious diseases. Excision has raised $70.74 million across 3 funding rounds from investors including HHS, Norwest Venture Partners and GreatPoint Ventures. Its chief executive, as recorded, is Daniel Dornbusch. Excision offers products and services including CRISPR Therapy for HIV, CRISPR Therapy for HSV, and CRISPR Therapy for Hepatitis B. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is Excision BioTherapeutics, Inc. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in San Francisco, California and is supported by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.
- Headquarters Philadelphia, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website excision.bio
- Social LinkedIn X Facebook Instagram
- Legal Name Excision Biotherapeutics, Inc.
- Total Equity Funding$70.74M (USD)
in 3 rounds
- Latest Funding Round$60.74M (USD), Series A
Feb 2021
- InvestorsHHS
& 9 more
Products & Services of Excision
Excision offers a comprehensive portfolio of products and services, including CRISPR Therapy for HIV, CRISPR Therapy for HSV, and CRISPR Therapy for Hepatitis B.
Edits viral DNA to eliminate HIV in infected cells.
Targets herpes simplex viruses for potential cure.
Disrupts hepatitis B viral DNA to reduce infection.
Funding Insights of Excision
Excision has successfully raised a total of $70.74M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $60.74 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $70.74M
- Total Rounds 3
- Last Round Series A β $60.74M
- First Round $10M
(Sep 2017)
- Investors Count 10
All 3 funding rounds of Excision with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $60.74M | Series A | β | GreatPoint Ventures, Celesta Capital | |
| Jun 2019 | $217,484 | Grant | β | β | |
| Sep 2017 | $10M | Seed | β | Artis Ventures | β |
10 investors in total: 10 institutional.
Investors in Excision
Excision has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Norwest Venture Partners and GreatPoint Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors | gpv.com | San Francisco, United States | ||
Early-stage startups are invested in by Artis Ventures. | av.co | San Francisco, United States | ||
Venture capital is deployed for global health technology innovations. | adjuvantcapital.com | New York City, USA | ||
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors. | 1961 | nvp.com | Menlo Park, United States | |
Investments are made in industrial and life sciences technology companies. | anzupartners.com | Washington, Dc, United States | ||
Provider of a venture capital firm that invests in technology and life sciences companies | olivetreecapital.com | Boston, United States | ||
Stage-agnostic venture capital investments are focused on US sectors. | cotacapital.com | San Francisco, United States | ||
Early-stage tech investments are made in India, US, and UK. | indusage.com | Bengaluru, India | ||
Venture capital firm focused on multiple sectors | celesta.vc | San Francisco, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Excision
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Excision
42 people are tracked at Excision (12 in leadership, 21 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Daniel Dornbusch | CEO | Leadership |
Salvatore Amato | Senior Director, Finance | Leadership |
Qin Xiang | Director, Analytical Development & QC | Leadership |
Elvin Ruan | Senior Director, Genome Editing | Leadership |
Ryo Takeuchi | Director, Genome Editing | Leadership |
Franz Gerner | CTO | Leadership |
TJ Cradick | Chief Scientific Officer | Leadership |
Ann Branca | VP, Clinical Operations in Clinical Development & Operations | Leadership |
Christine Silverstein | CFO | Leadership |
Meriza Viray | Director, Clinical Operations | Leadership |
Helen Zhao | Senior Director, Project Management | Leadership |
Nadia Amrani | Associate Director, Genome Editing | Leadership |
Toni Cathomen | Scientific Advisory Board Member | Board & advisors |
Joseph Berger | Scientific Advisory Board Member | Board & advisors |
Kenneth L. Tyler | Scientific Advisory Board Member | Board & advisors |
John Baxter | Scientific Advisory Board Member | Board & advisors |
David Clifford | Scientific Advisory Board Member | Board & advisors |
Timothy M. Block | Scientific Advisory Board | Board & advisors |
Vasudev Bailey | Director | Board & advisors |
Keith Jerome | Scientific Advisory Board Member | Board & advisors |
22 more people are available in the full profile.
Complete people profiles for Excision
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Excision
3 dated milestones of Excision across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Excision is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series A, of $60.7M.
Competitors of Excision
Excision has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Excision
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Excision
The website of Excision (excision.bio) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 55.4% vs previous month
Websites whose visitors overlap most with Excision. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| r2mpharma.com | 100% | 2.9K | #4,331,217 | View details | |
| aligos.com | 98% | 3.4K | #3,982,602 | View details | |
| astellasgenetherapies.com | 98% | 1K | View details | ||
| quantatx.com | 96% | 3.1K | #5,909,422 | View details | |
| shennonbio.com | 96% | View details | |||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 30 similar websites and full traffic analytics for Excision
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 30 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Excision (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 87.11 M | 4,647 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Excision
Complete news archive for Excision
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Excision
Excision was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Excision is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Daniel Dornbusch is the CEO of Excision, as recorded in our data.
Excision is a funded company, having raised a total of $70.74M across 3 funding rounds to date. The company's 1st funding round was a Seed of $10M, raised on Sep 2017.
Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases. Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the Company has already demonstrated the first functional cure for HIV in animals. Excision is developing technologies and IP developed at Temple University and U.C. Berkeley. Excision is located in San Francisco, California and is supported by ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.
Excision's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Excision offers CRISPR Therapy for HIV, CRISPR Therapy for HSV, and CRISPR Therapy for Hepatitis B.
Excision has 10 investors. Key investors include HHS, Norwest Venture Partners, GreatPoint Ventures, Artis Ventures, and Adjuvant Capital.
Excision operates through Excision Biotherapeutics, Inc..
